Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia

Blood

Volumn 127, Issue 21, 2016, Pages 2598-2606

  Roccaro, Aldo M ^a,b   Sacco, Antonio ^a   Shi, Jiantao ^c   Chiarini, Marco ^a,b   Perilla Glen, Adriana ^a   Manier, Salomon ^a   Glavey, Siobhan ^a   Aljawai, Yosra ^a   Mishima, Yuji ^a   Kawano, Yawara ^a   Moschetta, Michele ^a   Correll, Mick ^a   Improgo, Ma Reina ^a   Brown, Jennifer R ^a   Imberti, Luisa ^b   Rossi, Giuseppe ^b   Castillo, Jorge J ^a   Treon, Steven P ^a   Freedman, Matthew L ^a   Van Allen, Eliezer M ^a   Hide, Winston ^d   Hiller, Elaine ^a   Rainville, Irene ^a   Ghobrial, Irene M ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b SPEDALI CIVILI   (Italy)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; B LYMPHOCYTE RECEPTOR; CYTOKINE RECEPTOR; GENOMIC DNA; HCLS1 G496A PROTEIN; JANUS KINASE; LAPTM5 C403T PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN; STAT PROTEIN; TNFAIP3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; HCLS1 PROTEIN, HUMAN; LAPTM5 PROTEIN, HUMAN; MEMBRANE PROTEIN; PLASMA PROTEIN;

ALGORITHM; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL; CONTROLLED STUDY; EXOME; FAMILIAL DISEASE; FAMILY HISTORY; FIRST DEGREE RELATIVE; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; GERM LINE; HETEROZYGOTE; HUMAN; LARGE CELL LYMPHOMA; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SOLID TUMOR; SOMATIC MUTATION; WALDENSTROEM MACROGLOBULINEMIA; CLINICAL TRIAL; FAMILY; FEMALE; GENETICS; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; MALE;

BLOOD PROTEINS; EXOME; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MEMBRANE PROTEINS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84974621496     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-680199     Document Type: Article

References (48)

1. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10(12):1419-1432.
2. Gertz MA. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015;90(4):346-354.
3. Buske C, Leblond V. How to manage Waldenstrom's macroglobulinemia. Leukemia. 2013;27(4):762-772.
4. Kyle RA, Dispenzieri A, Kumar S, Larson D, Therneau T, Rajkumar SV. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM). Clin Lymphoma Myeloma Leuk. 2011;11(1):74-76.
5. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102(10):3759-3764.
6. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367(9):826-833.
7. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637-1646.
8. Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120-4131.
9. Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia. Leukemia. 2015;29(1):169-176.
10. Blattner WA, Garber JE, Mann DL, et al. Waldenström's macroglobulinemia and autoimmune disease in a family. Ann Intern Med. 1980;93(6):830-832.
11. Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052-3056.
12. Massari R, Fine JM, Metais R. Waldenstrom's macroglobulinaemia observed in two brothers. Nature. 1962;196:176-178.
13. McMaster ML, Csako G, Giambarresi TR, et al. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res. 2007;13(17):5063-5069.
14. Renier G, Ifrah N, Chevailler A, Saint-Andre JP, Boasson M, Hurez D. Four brothers with Waldenstrom's macroglobulinemia. Cancer. 1989;64(7):1554-1559.
15. Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML. Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. Blood. 2010;115(22):4464-4471.
16. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17(3):488-494.
17. Crowther-Swanepoel D, Houlston RS. The molecular basis of familial chronic lymphocytic leukemia. Haematologica. 2009;94(5):606-609.
18. McMaster ML, Goldin LR, Bai Y, et al. Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet. 2006;79(4):695-701.
19. Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet. 2012;44(1):58-61.
20. Chubb D, Weinhold N, Broderick P, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013;45(10):1221-1225.
21. Swaminathan B, Thorleifsson G, Jöud M, et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun. 2015;6:7213.
22. Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-525.
23. Kuppusamy H, Ogmundsdottir HM, Baigorri E, et al. Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer. PLoS One. 2014;9(6):e100691.
24. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(4):1754-1760.
25. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat. 2013;34(9):E2393-E2402.
26. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498.
27. Cingolani P, Platts A, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80-92.
28. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
29. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
30. Raychaudhuri S, Plenge RM, Rossin EJ, et al; International Schizophrenia Consortium. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet. 2009;5(6):e1000534.
31. Obayashi T, Okamura Y, Ito S, Tadaka S, Motoike IN, Kinoshita K. COXPRESdb: a database of comparative gene coexpression networks of eleven species for mammals. Nucleic Acids Res. 2013;41(Database issue):D1014-D1020.
32. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc. 2009;4(3):363-371.
33. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
34. Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009;69(8):3579-3588.
35. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
36. Trynka G, Sandor C, Han B, et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet. 2013;45(2):124-130.
37. Benita Y, Cao Z, Giallourakis C, Li C, Gardet A, Xavier RJ. Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. Blood. 2010;115(26):5376-5384.
38. Scott LM, Mueller L, Collins SJ. E3, a hematopoietic-specific transcript directly regulated by the retinoic acid receptor alpha. Blood. 1996;88(7):2517-2530.
39. Takemoto Y, Sato M, Furuta M, Hashimoto Y. Distinct binding patterns of HS1 to the Src SH2 and SH3 domains reflect possible mechanisms of recruitment and activation of downstream molecules. Int Immunol. 1996;8(11):1699-1705.
40. Huttenhower C, Haley EM, Hibbs MA, et al. Exploring the human genome with functional maps. Genome Res. 2009;19(6):1093-1106.
41. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica. 2012;97(9):1281-1290.
42. Pers TH, Karjalainen JM, Chan Y, et al; Genetic Investigation of ANthropometric Traits (GIANT) Consortium. Biological interpretation of genome-wide association studies using predicted gene functions. Nat Commun. 2015;6:5890.
43. May RM, Okumura M, Hsu CJ, et al. Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function. Blood. 2013;121(16):3135-3146.
44. Gutiérrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia. 2007;21(3):541-549.
45. Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia. Leukemia. 2015;29(1):169-176.
46. Seimiya M, O-Wang J, Bahar R, et al. Stage-specific expression of Clast6/E3/LAPTM5 during B cell differentiation: elevated expression in human B lymphomas. Int J Oncol. 2003;22(2):301-304.
47. Glowacka WK, Alberts P, Ouchida R, Wang JY, Rotin D. LAPTM5 protein is a positive regulator of proinflammatory signaling pathways in macrophages. J Biol Chem. 2012;287(33):27691-27702.
48. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008;111(10):5068-5077.